Islatravir and Lenacapavir Show Sustained Virologic Suppression in Phase 3 HIV Trials
Phase 3 ISLEND trials demonstrated high rates of virologic suppression at week 48 for the ISL/LEN regimen.
Asset / Drug
Drug and asset intelligence for Islatravir with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Gilead and Merck announced positive topline results from two Phase 3 studies for Islatravir/Lenacapavir, a novel oral HIV treatment.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.